VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount of $5.43 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2020 was $5.43M, a 12.06% decline from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2019 was $6.18M, a 73.63% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2018 was $23.43M, a 69.89% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2017 was $77.80M, a 264.48% increase from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount 12 month | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount 12 month as first filed |
|---|---|---|
| 2020-12-31 | $5.43M 10-K · filed 2021-02-11 | |
| 2019-12-31 | $6.18M 10-K · filed 2021-02-11 | |
| 2018-12-31 | $23.43M 10-K · filed 2021-02-11 | |
| 2017-12-31 | $77.80M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $21.35M 10-K · filed 2019-02-13 | |
| 2015-12-31 | $47.40M 10-K · filed 2018-02-15 | |
| 2014-12-31 | $39.34M 10-K · filed 2017-02-23 | |
| 2013-12-31 | $79.80M 10-K · filed 2016-02-16 | $72.96M 10-K · filed 2014-02-11 |
| 2012-12-31 | $46.17M 10-K · filed 2015-02-13 | $62.42M 10-K · filed 2013-03-01 |
| 2011-12-31 | $43.63M 10-K · filed 2014-02-11 | |
| 2010-12-31 | $632.00K 10-K · filed 2013-03-01 | |
| 2009-12-31 | $674.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |